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Data on features of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) in children and adoles-
cents are scarce. We report preliminary results of an 
Italian multicentre study comprising 168 laboratory-
confirmed paediatric cases (median: 2.3 years, range: 
1 day–17.7 years, 55.9% males), of which 67.9% were 
hospitalised and 19.6% had comorbidities. Fever was 
the most common symptom, gastrointestinal mani-
festations were frequent; two children required inten-
sive care, five had seizures, 49 received experimental 
treatments and all recovered.
Since the end of December 2019, coronavirus disease 
(COVID-19) caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) has rapidly spread 
worldwide becoming the first pandemic of the 21st cen-
tury. Despite the high number of people affected, data 
on clinical features and prognostic factors in children 
and adolescents are limited.
We report the preliminary results of a national multicen-
tre study, promoted by the Italian Society of Paediatric 
Infectious Diseases (SITIP), within the Italian Society 
of Paediatrics (SIP). The study investigates epidemio-
logical, clinical and therapeutic aspects of SARS-CoV-2 
infection in infants, children and adolescents, hereaf-
ter referred to as paediatric population or children.
Participating physicians, hospitals and 
patients
The multicentre study involves 11 of 13 exclusively 
paediatric hospitals and 51 of 390 paediatric units 
across Italy, but predominantly in central and northern 
regions. Of approximately 15,900 paediatricians work-
ing in the national health system, more than 10,000 are 
members of SIP. Retrospective data collection started 
on 25 March 2020.
The presented data include all paediatric patients in 
whom COVID-19 was documented by at least one nasal/
pharyngeal swab specimen positive for SARS-CoV-2 
nucleic acid using real-time reverse-transcriptase pol-
ymerase-chain-reaction (RT-PCR) assay.
Ethical approval of the ethical committee of the coor-
dinating Centre in Turin (Comitato Etico Interaziendale 
AOU Città della Salute e della Scienza di Torino – AO 
Ordine Mauriziano di Torino – ASL Città di Torino) was 
provided on 24 March 2020, protocol number 0031296. 
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Data collection was allowed by written consent of at 
least one parent; patients’ data were de-identified.
Findings
As at 10 April 2020, data for 168 children aged 1 day 
to 17 years, 94 (55.9%) males and 74 (40.1%) females, 
with confirmed COVID-19 and an adequate follow-up 
were available. Adequate follow-up was the period 
considered necessary by the clinician to define the 
final outcome, in most instances at least 2 weeks. The 
mean age was 5 years (median: 2.3 years, interquartile 
range (IQR): 0.3–9.6 years); 15 were neonates (Table). 
The majority of children (65.1%) were hospitalised: of 
these, only 17 (15.5%) were referred to hospital after 
seeing a paediatrician or family doctor. Hospital admis-
sion was inversely related to age (p < 0.01; Fisher exact 
test); among infected children under 1 year of age, 
52/66 were hospitalised vs 24/38, 13/24 and 21/40 
among the 1 to 5 year-olds, 6 to 10 year-olds and over 
10 year-olds, respectively.
Thirty-three children (19.6%) had underlying chronic 
diseases, such as chronic lung disease (n = 7), congen-
ital malformations or complex genetic syndromes (n = 
14), cancer (n = 4), epilepsy (n = 5), gastrointestinal 
(n = 2) or metabolic disorders (n = 1) and seven were 
immunosuppressed (n = 4) or immunocompromised (n 
= 3). The hospitalisation rate was similar between chil-
dren with comorbidities and those without (23/33 vs 
87/135, respectively; p = 0.68, Fisher exact test).
Close contact with a COVID-19 infected person out-
side the family was rarely reported; conversely, 67.3% 
(113/168) of children had at least one parent who tested 
positive for SARS-CoV-2 infection. Symptom onset in 
relatives frequently (88/113, 77.8%) preceded symp-
toms in the infected child between 1 to 14 days.
All but four (2.5%) enrolled children were sympto-
matic. Fever ranging from 37.5 to 39 °C was the most 
common symptom (82.1%), followed by cough (48.8%) 
and rhinitis (26.8%). Interestingly, 31 children (18.4%) 
developed gastrointestinal symptoms (vomiting and/
or diarrhoea), while five had seizures; of these, three 
children had a known history of epilepsy, one child 
had a past history of febrile seizures and the remaining 
one had a first episode of febrile seizures as onset of 
COVID-19e and SARS-CoV-2 encephalitis was ruled out. 
The mean interval between symptom onset and first 
medical evaluation was 1.6 days (range: 0–18).
In children who underwent blood investigations, the 
increase of C-reactive protein above 0.5 mg/dl was 
the most common finding (47/121, 38.8%), while other 
alterations frequently encountered in adults, such as 
leukopenia, neutropenia, lymphopenia, increased CK 
or LDH values, were rare (data not shown).
Complications and co-infections
Thirty-three children (19.6%) developed complications, 
such as interstitial pneumonia (n = 26), severe acute 
respiratory illness (n = 14) and peripheral vasculitis (n 
= 1); two of the 33, a preterm neonate and a 2-month-
old infant with congenital heart disease, required 
intensive care unit (ICU) admission and treatment with 
mechanical ventilation. Non-invasive oxygen-treatment 
was administered to 16 of 168 (9.5%) children. No child 
underwent chest computed tomography scan; pneumo-
nia was assessed either by X-ray or ultrasound in 75 of 
the children.
A viral co-infection was documented in 10 children 
(5.9%), including three respiratory syncytial virus, 
three rhinovirus, two Epstein-Barr virus, one influenza 
A virus and one non-SARS coronavirus infection. A bac-
terial co-infection with Streptococcus pneumoniae was 
also documented.
Table
Characteristics of SARS-CoV-2-infected children, Italy, as 
at 10 April 2020 (n = 168)
Parameter Total (n) Percentage (%)
Age (years)
Mean, median (IQR) 5, 2.3 (0.3–9.6) NA
Age groups
< 1 yeara 66 39.3
1–5 years 38 22.6
6–10 years 24 14.3
11–17 years 40 23.8
Sex
Males 94 55.9
Females 74 44.1
Signs and symptomsb
Fever ranging from 37.5–39°C 138 82.1
Cough 82 48.8
Rhinitis 45 26.8
Diarrhoea 22 13.1
Dyspnoea 16 9.5
Pharyngitis 9 5.4
Vomiting 9 5.4
Conjunctivitis 6 3.6
Chest pain 4 2.4
Fatigue 3 1.8
Non-febrile seizures 3 1.8
Febrile seizures 2 1.2
Hospital admission within age groups
< 1 year 52 78.8
1–5 years 24 63.2
6–10 years 13 54.2
11–17 years 21 52.5
Total 110 65.1
IQR: interquartile range; NA: not applicable; SARS-CoV-2: severe 
acute respiratory syndrome coronavirus 2.
a Of coronavirus disease (COVID-19) cases in this age group, 15 of 
66 were less than 4 weeks of age.
b Several answers were possible.
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Antiviral treatment
Experimental treatments for SARS-CoV-2 infection, 
including lopinavir/ritonavir (lopinavir component: 230 
mg/m2 of body surface area twice daily), hydroxychlo-
roquine (2.5 mg/kg twice daily) and/or azithromycin 
(10 mg/kg once daily)/clarithromycin (7.5 mg/kg twice 
daily), were administered to 49 children (29.2%). A 
systemic steroid was administered only in one case. 
Antiviral treatments were preferentially given to chil-
dren who were more severely ill (data not shown).
Discussion
SARS-CoV-2 infection in children differs from adult dis-
ease with respect to clinical manifestations and out-
come. Our data confirmed that case fatality in children 
is very low: only a few fatal COVID cases have been 
reported in the literature thus far [1-3]. In our series, 
all children, including those with comorbidities, recov-
ered fully, and no sequelae were reported at the time 
of submission.
Italy has been among of the countries most affected 
by COVID-19, with more than 140,000 infected cases 
and around 17,000 deaths as at 10 April 2020 [4]. The 
number of cases and case-fatality rate in Italian adults 
with COVID-19 are higher compared with many other 
countries [5]. This may be because of an older mean 
population age, higher frequency of comorbidities in 
the older population, and the limited number of rhino-
pharyngeal swabs performed on asymptomatic people 
during the initial phase of the Italian epidemic. In this 
scenario, data from our paediatric multicentre study 
confirm the different course of the infection in the pae-
diatric age group: children were a marginal percentage 
of the Italian infected population admitted to hospi-
tal and tended to develop benign, pauci-symptomatic 
disease.
The contribution of children to disease transmission is 
still under debate, including whether they might serve 
as facilitators of viral transmission, being a silent res-
ervoir for the virus. Many hypotheses have been formu-
lated on the mechanisms underlying children’s lower 
susceptibility to severe SARS-CoV-2 infection com-
pared with adults; these include an immature receptor 
system, specific regulatory mechanisms in the immune 
respiratory system and cross-protection by antibodies 
directed towards common viral infections in infancy 
[6]. However, nearly 40% of the children included in 
this report were under 1 year of age and the majority 
of them were hospitalised, suggesting a higher suscep-
tibility to symptomatic COVID-19 in this specific age 
group: the two children who required ICU admission 
were a neonate and a 2-month-old infant. However, 
the high number of children under 1 year of age in our 
study may also reflect both a higher tendency for fami-
lies to seek medical advice for younger children and a 
higher propensity among clinicians to admit them to 
hospitals. Also in the United States (US), hospitalisa-
tion was more common among children under 1 year of 
age than in other paediatric age groups, including ICU 
admission [1]. According to the Italian national public 
health institute’s surveillance report of 10 April, SARS-
CoV-2 infection affected a total of 1,936 children, of 
whom 5.2% were hospitalised; the percentage of hos-
pitalised children within the 0 to 1-year-old age group 
was 10.9%. A rough estimate of the general hospitali-
sation rate in the Italian paediatric population is 39.6 
per 1,000 children [7].
Similar to what was reported in paediatric studies 
from China and the US, we observed a slightly higher, 
although not statistically significant, prevalence in 
males in all age groups (data not shown), supporting 
the hypothesis that sex-linked genetic factors may 
influence susceptibility to COVID-19.
Fever was the most common encountered symptom 
in our cohort: this is in contrast with data reported 
in Chinese and US American children in whom fever 
was less common (36–56%) compared with cough 
or pharyngitis [1,2,8-10]. Conversely, proportions of 
gastrointestinal symptoms were similar among the 
three cohorts, ranging from 6.4 to 11% for nausea and 
vomiting and from 8.8 to 13% for diarrhoea [1,2,8-10]. 
Neurological manifestations, consisting in febrile and 
non-febrile seizures, were observed in 3% of children 
at onset of COVID-19, although none developed SARS-
CoV-2-related encephalitis.
Although only preliminary data are presented, our study 
has several limitations. First, our population includes 
children and adolescents under 18 years of age: this 
make some results difficult to compare with other pub-
lications that consider children and adolescents up to 
15 or 16 years. Secondly, the limited sample size for 
some analyses does not allow to draw definite conclu-
sions. For example, because of small numbers and dif-
ferences in demographic conditions between children 
who did vs did not receive antiviral treatments, clini-
cal progression of treated and untreated children could 
not be compared. Also, with a wider population, spe-
cific comparison and analysis in different age groups 
should be looked specifically at.
Despite these limitations, this is to our knowledge the 
largest cohort on the characteristics of laboratory-
confirmed COVID-19 in European children. At present, 
most of the paediatric data are from Chinese studies; 
of these, many also included children without a labo-
ratory diagnosis and in them, the disease seems to 
have taken a more severe course than in children with 
laboratory-confirmed disease [8]. According to some 
authors, this may be because a number of children 
improperly categorised as having COVID-19 might have 
been infected by other aggressive pathogens [11].
In conclusion, our findings show a favourable clinical 
course of COVID-19 infection in children and adoles-
cents in Italy, where the case-fatality rates observed 
in adults seem high compared with several other coun-
tries. Consequently, the diagnostic, clinical and even 
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therapeutic approach in children might be more con-
servative than in adults, for example reserving chest 
computed tomography scan, hospital admission and 
antiviral treatments (unless more effective and safe 
drugs will become available) to selected situations.
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